• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, April 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Insilico to present the advances in Artificial Intelligence for Healthcare in Nigeria

Bioengineer by Bioengineer
May 2, 2018
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Insilico Medicine

Wednesday, May 2, 2018, Baltimore, MD – Insilico Medicine, a Baltimore-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the talk of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the Annual General Conference and Delegates Meeting: Abuja 2018, May 4, 2018, Abuja, Nigeria.

Ogu's presentation "Building the African pharmaceutical industry and the future of longevity with next-generation artificial intelligence" will be devoted to the recent advances in AI tending to become a growth engine for African biopharmaceutical industry and transform the R&D in local pharmaceutical companies. The talk will also focus on the challenges of African pharmaceutical sector and educational opportunities for building the strong local teams interested in the application of AI to drug discovery.

"We are very happy to present our work at Annual General Conference and Delegates Meeting: Abuja 2018, which brings together many Nigerian thought leaders in healthcare. The topic of Artificial Intelligence for pharma R&D is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

"The immense amount of medical data are being generated daily, and these data could be channeled towards better products in healthcare and beyond. However, people underestimate the value of personal data including medical records, especially in Africa. At the same time, there is a clear need to develop better solutions to many global and local African healthcare challenges. Hence, we can converge advances in next-generation artificial intelligence and blockchain to accelerate developments in many aspects of healthcare and beyond", said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant of Insilico Medicine, Inc.

The Annual General Conference and Delegates Meeting: Abuja 2018 is organized by Nigerian Medical Association – the largest medical association in the West African sub-region with over 40000 members. The event's organizers aim to gather the Nigerian medical doctors and other healthcare specialists and unite them around the problems in quality healthcare delivery. The conference will be held on May 4, 2018.

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first who applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. The paper published in Molecular Pharmaceutics in 2016 demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. A recent paper published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in Oncotarget presented the roadmap to enhancing radioresistance for space exploration and colonization.

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
[email protected]
Website: http://www.Insilico.com

Official Conference Website: http://www.nationalnma.org/2018/04/24/2018-annual-general-conference-and-delegates-meeting-abuja-2018/

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Media Contact

Qingsong Zhu
[email protected]
443-451-7212
@InSilicoMeds

http://www.insilicomedicine.com

Original Source

http://nationalnma.org/2018/04/24/2018-annual-general-conference-and-delegates-meeting-abuja-2018/

Share12Tweet8Share2ShareShareShare2

Related Posts

FGFR1 Halts Ovarian Cancer via Metabolic Shift

April 7, 2026

Breakthrough in Epilepsy Research: Scientists Successfully Reverse Severe Seizures in Lab Mice, Paving the Way for a Potential Cure

April 7, 2026

Mount Sinai Establishes Adams Valve Institute to Advance Complex Valve Surgery and Valvular Heart Disease Treatment

April 7, 2026

Small-Volume Hypertonic Saline Combined with Furosemide Reduces Inflammatory and Remodeling Markers in Acute Heart Failure

April 7, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    98 shares
    Share 39 Tweet 25
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1009 shares
    Share 399 Tweet 249
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Pioneering Multimodal Intelligence to Revolutionize Colonoscopy

FGFR1 Halts Ovarian Cancer via Metabolic Shift

Southwest Research Institute Unveils 2025 Internal Research & Development Report

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.